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Background. Both human immunodeficiency virus (HIV) infection and antiretroviral therapy (ART) may increase cardiovascu-
lar disease (CVD) risk. Vascular function assessments can be used to study CVD pathogenesis. We compared the effect of immediate 
versus deferred ART initiation at CD4 counts >500 cells/mm3 on small arterial elasticity (SAE) and large artery elasticity (LAE).
Methods. Radial artery blood pressure waveforms were recorded noninvasively. Small arterial elasticity and LAE were derived 
from analysis of the diastolic pulse waveform. Randomized treatment groups were compared with linear models at each visit and 
longitudinal mixed models.
Results. Study visits involved 332 participants in 8 countries: mean (standard deviation [SD]) age 35 (10), 70% male, 66% non-
white, 30% smokers, and median CD4 count 625 cells/mm3 and 10-year Framingham risk score for CVD 1.7%. Mean (SD) SAE and 
LAE values at baseline were 7.3 (2.9) mL/mmHg × 100 and 16.6 (4.1) mL/mmHg × 10, respectively. Median time on ART was 47 
and 12 months in the immediate and deferred ART groups, respectively. The treatment groups did not demonstrate significant with-
in-person changes in SAE or LAE during the follow-up period, and there was no difference in mean change from baseline between 
treatment groups. The lack of significant differences persisted after adjustment, when restricted to early or late changes, after censor-
ing participants in deferred group who started ART, and among subgroups defined by CVD and HIV risk factors.
Conclusions. Among a diverse global population of HIV-positive persons with high CD4 counts, these randomized data suggest 
that ART treatment does not have a substantial influence on vascular function among younger HIV-positive individuals with pre-
served immunity.
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Human immunodeficiency virus (HIV)-positive persons are at 
increased risk for premature cardiovascular disease (CVD) [1], 
which is now a leading cause of morbidity and mortality among 
patients treated with antiretroviral therapy (ART) [2]. The under-
lying pathology of CVD among HIV-positive persons includes 
atherosclerotic disease, as well as associated vascular abnormal-
ities such as endothelial dysfunction and hypertension [3, 4]. 
Factors contributing to excess CVD risk among HIV-positive 
persons include a greater prevalence of traditional risk factors (eg, 
smoking, lipid abnormalities) and consequences of HIV disease—
such as HIV replication, immune deficiency, and exposure to cer-
tain antiretroviral medications [5–8]. Recent data also emphasize 
the central importance of systemic inflammation, which itself may 
improve but persist at elevated levels with ART [9, 10].
Given the potential for ART initiation to both increase (via 
drug toxicity) and decrease (via HIV viral suppression) CVD 
risk, it is important to study this complex pathophysiology in 
the context of randomized comparisons. The Strategic Timing 
of AntiRetroviral Therapy (START) trial is a randomized con-
trolled clinical trial of immediate initiation of ART (“imme-
diate” group) versus deferral of ART initiation until clinical 
symptoms develop or CD4+ counts decline to <350 cells/mm3 
(“deferred” group), among patients naive to ART with CD4+ 
counts >500 cells/m3 at baseline. The START is an ideal study 
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design to compare CVD risk between untreated and ART-
treated HIV infection in a controlled fashion.
Prognostic markers of vascular disease are useful tools 
to detect early CVD. Carotid artery intima media thickness 
(CIMT) and coronary artery calcified plaque (CAC) are struc-
tural markers for CVD. In contrast, functional markers for CVD 
include arterial stiffness (the inverse of elasticity) or endothe-
lial dysfunction (eg, assessed via brachial artery flow-mediated 
dilation). Functional markers have value for early detection 
of CVD before changes in structural markers are detected 
[11]. We have previously reviewed noninvasive techniques for 
assessing vascular function and the rationale for utilizing blood 
pressure (BP) waveform analysis in the START trial [12]. Our 
approach estimating arterial elasticity is responsive to interven-
tions (eg, statins or angiotensin receptor blockers) [13, 14], is 
highly reproducible with repeated measures [15], and has been 
independently associated with subsequent coronary heart dis-
ease, stroke, congestive heart failure, and incident hypertension 
in the general population [16–18]. In this study, we report the 
primary results of the START Arterial Elasticity Substudy.
METHODS
Design and Sample Size Considerations
The design and primary findings from the START trial have 
been described previously [19, 20], and the experimental ran-
domized intervention is described above. The primary hypoth-
esis was that immediate initiation of ART would increase 
(improve) both small artery elasticity (SAE) and large artery 
elasticity (LAE), respectively, compared with deferred ART ini-
tiation. After informed consent, participants were randomized 
and study data collection occurred at baseline, at months 4, 8, 
and 12, and then annually thereafter. The coprimary outcome 
measures were changes from baseline in SAE and LAE, over an 
average of all follow-up visits. The study was designed to coen-
roll at least 300 participants. Assuming standard deviations 
(SDs) of 3.0 mL/mmHg × 100 for SAE and 5.0 mL/mmHg × 
10 for LAE, the substudy had 80% power to detect a difference 
between groups of 1.2 mL/mmHg × 100 in SAE and 1.9 mL/
mmHg × 10 in LAE. Based on epidemiologic data from 6235 
participants in the Multi-Ethnic Study of Atherosclerosis 
(MESA), a 1.2-unit change in SAE corresponds to an effect size 
of 0.4 SD units for men and 0.5 SD units for women [21]; corre-
sponding differences in absolute CVD event risk would then be 
11% for men and 15% for women [16]. The study protocol was 
approved by ethics committees at the University of Minnesota 
and all participating clinical centers.
Clinical and Laboratory Data
Demographic and clinical data were collected as part of the 
main START trial [20]. Human immunodeficiency virus rib-
onucleic acid (RNA) level and CD4 count were ascertained at 
every visit, and blood cholesterol levels were obtained annually. 
Ten-year clinical CVD risk was estimated using the following: 
(1) Framingham Risk Score (FRS) for a CVD event [22], and 
(2) the pooled cohort risk assessment for atherosclerotic CVD 
(ASCVD) event [23]. Glomerular filtration rate was estimated 
using the Chronic Kidney Disease Epidemiology Collaboration 
formula.
Blood Pressure Waveform Analysis to Estimate Arterial Elasticity
Radial artery BP waveforms were recorded using the HDI/
PulseWave CR-2000 (Hypertension Diagnostics, Inc., Eagan, 
MN). A solid-state pressure transducer array (tonometer) was 
placed over the radial artery of the dominant arm to record the 
BP contour. A 30-second analog tracing of the radial BP wave-
form, constituting pressure changes during diastole, was digi-
talized at 200 samples per second. An automated, oscillatory BP 
measurement was ascertained at the brachial artery of the con-
tralateral arm. Arterial elasticity was estimated by modeling the 
diastolic BP waveform as a decaying exponential function plus 
a sinusoidal function dampened by a decaying exponential, as 
previously described [24]. This approach treats the circulatory 
system as a modified Windkessel model, considering the arte-
rial system a network of vessels designed to convert intermittent 
flow from the heart to a continuous and steady flow across the 
capillaries. The model then characterizes capacitance and resist-
ance factors to estimate 2 parameters (Supplemental Figure A): 
(1) the distal arterial compliance, or oscillatory compliance 
(C2), referred to as SAE; and (2) the proximal arterial compli-
ance, or capacitance compliance (C1), referred to as LAE.
The procedures for obtaining a BP waveform are consistent 
with established protocols using this technique in large CVD 
cohorts [16, 18, 21, 25]. Participants are instructed to avoid 
caffeine, alcohol, nicotine, antihistamines, and nonsteroidal 
anti-inflammatory drugs before the study visit. Research staff 
were trained to measure BP waveform, and they were certified 
based on the quality of waveform measures from 3 separate vol-
unteers as assessed by 2 independent reviewers. Research staff 
were recertified on BP waveform procedures annually. During 
study visits, waveform measures were performed in triplicate 
to reduce short-term biologic variability, and averages from 
each visit were used for analyses. The BP waveform data from 
each study visit was evaluated (blinded to treatment group) for 
waveform quality, with focus on appropriate morphology. Only 
waveforms passing qualitative review were included in analyses. 
To assess intraoperator repeatability of arterial elasticity meas-
urements, study staff performed duplicate BP waveform assess-
ments, each on a single volunteer separated by 30–120 minutes. 
The difference and correlation between repeatability measures 
were summarized.
Statistical Methods
Analyses for the coprimary endpoint (change in SAE and 
LAE) were by intention to treat, comparing the immediate and 
deferred ART arms. All participants with an acceptable baseline 
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BP waveform were included in the analyses. Baseline and demo-
graphic summaries are presented as percentages and medians with 
25th and 75th percentiles. General linear models were used to 
compare the treatment arms for change in arterial elasticity at each 
visit, and a longitudinal mixed model with an unstructured covar-
iance matrix was used to estimate the overall change from base-
line. The prespecified level of significance was set at alpha <0.025 
(2-sided), given the 2 coprimary endpoints. Overall changes from 
baseline were also estimated with longitudinal mixed models for 
predefined subgroups, including age, gender, ethnicity, current 
smoking status, body mass index (BMI), systolic BP (SBP), dias-
tolic BP (DBP), Framingham CVD risk score, CD4 cell counts, 
HIV RNA levels, and duration of HIV infection. All models for 
change in SAE and LAE were adjusted for baseline value.
RESULTS
Quality and Repeatability of Arterial Elasticity Measures
Among 2021 study visits involving 332 participants, 1991 (99%) 
visits had ≥1 BP waveform pass qualitative review. Among the 
1961 study visits with ≥2 acceptable waveforms, the average 
within-person SD was 0.87 mL/mmHg × 100 (CV = 0.11) for 
SAE measurements and 1.67 mL/mmHg × 10 (CV = 0.10) for 
LAE measurements. Of 27 study staff who performed duplicate 
BP waveform assessments on the same volunteer, separated by 
30–120 minutes, the mean (±SD) difference between the dupli-
cate measurements was 0.05 ± 1.64 mL/mmHg × 100 for SAE 
and −0.10  ±  2.55  mL/mmHg × 10 for LAE. The correlation 
between the duplicate measurements was 0.72 and 0.71 for SAE 
and LAE measurements, respectively.
Participant Characteristics
Of 431 participants randomized to the main START study after 
the Arterial Elasticity Substudy opened, 336 participants (78%) 
from 21 sites and 10 countries were coenrolled and randomized 
into the substudy from 2009 to 2012. Of these, 332 participants 
had baseline BP waveforms that passed qualitative review and 
are included in the analysis cohort. Baseline demographics are 
shown (Table 1). This diverse study sample was at very low risk 
for CVD. The median values for BMI, BP, and blood cholesterol 
levels were within normal ranges. By chance, there were more 
participants in the deferred versus immediate ART group tak-
ing lipid-lowering therapy (5.2% vs 0.6%, respectively; P = .01) 
and with a prior history of CVD (2.6% vs 0.0%, respectively; 
P = .03). Several of the other traditional CVD risk factors were 
slightly higher among deferred group participants, including 
the FRS and ASCVD pooled cohort 10-year risk score (P = .05). 
Finally, among this substudy of START, there was 1 CVD event 
(in the deferred group) during follow-up.
Baseline Small and Large Artery Elasticity Measurements
Median measures of SAE and LAE were 7.2 (interquartile range 
[IQR], 5.2–9.3) mL/mmHg × 100 and 16.3 (IQR, 13.6–19.3 mL/
mmHg × 10), respectively (Table 1). Baseline distributions of SAE 
and LAE and associations with traditional CVD risk factors have 
been previously reported [12]. At baseline, both SAE and LAE were 
lower (impaired) with increased age, female gender, and increased 
SBP and DBP; SAE was lower for those with a history of CVD and 
a higher 10-year CVD risk by FRS [12]. Neither HIV RNA level 
nor CD4+ count were associated with baseline SAE or LAE [12].
Antiretroviral Therapy Treatment and Follow-up
Median duration of follow-up was 48 (IQR, 40–59) months. 
Six percent of study participants (n = 20; 11 in immediate and 
9 in deferred group) withdrew or were lost to follow-up, and 
84% (n = 280) of participants completed a month 36 study visit 
(36% completed a month 48 visit). Median time on ART was 47 
(IQR, 39–59) and 12 (IQR, 0–31) months in the immediate and 
deferred ART groups, respectively. The percentage of those on 
ART among immediate and deferred groups were 96% and 18% 
at month 12, 97% and 30% at month 24, and 96% and 48% at 
month 36, respectively.
Table 1. Baseline Characteristics of START Arterial Elasticity Substudy 
(N = 332)
Participant Characteristics Immediate Deferred
Number of Participants 178 154
Demographics
Female gender, N (%) 54 (30.3%) 46 (29.9%)
Age, median years (IQR) 33 (27–40) 34 (29–43)
Race/Ethnicity, N (%)
 White 57 (32.0%) 56 (36.4%)
 Black 45 (25.3%) 35 (22.7%)
 Asian 63 (35.4%) 58 (37.7%)
 Latino/Hispanic 9 (5.1%) 5 (3.2%)
 Other 4 (2.2%) 0 (0.0%)
Clinical History
Sexual risk factor, N (%) same-sex exposure 103 (57.9%) 83 (53.9%)
Hepatitis B or C, N (%) 15 (8.4%) 12 (7.8%)
Diabetes, N (%) 3 (1.7%) 4 (2.6%)
Smoking, N (%) 52 (29.2%) 47 (30.5%)
Prior CVD, N (%) 0 (0.0%) 4 (2.6%)
BP-lowering therapy, N (%) 8 (4.5%) 9 (5.8%)
Lipid-lowering therapy, N (%) 1 (0.6%) 8 (5.2%)
Duration HIV positive, median years (IQR) 1.2 (0.4–3.0) 1.3 (0.4–3.5)
Clinical Data
BMI, median kg/m2 (IQR) 23 (21–26) 23 (21–26)
Systolic BP, median mmHg (IQR) 119 (112–129) 121 (113–133)
Diastolic BP, median mmHg (IQR) 74 (68–80) 75 (68–81)
10-yr CVD risk (FRS), median (IQR) 1.5 (0.4–4.4) 1.9 (0.7–6.1)
10-yr ASCVD risk, median (IQR) 0.8 (0.2–2.4) 1.0 (0.3–2.9)
eGFR, median mL/min/1.732 (IQR) 113 (100–123) 111 (98–121)
CD4 cell count, median cells/mm3 (IQR) 616 (563–730) 634 (562–726)
HIV RNA, median log10 copies/mL (IQR) 4.2 (3.7–4.7) 4.2 (3.6–4.7)
SAE, median mL/mmHg ×100 (IQR) 7.6 (5.5–9.4) 6.8 (5.0–8.8)
LAE, median mL/mmHg ×10 (IQR) 16.9 (13.7–19.5) 15.7 (13.3–18.3)
Abbreviations: ASCVD, atherosclerotic cardiovascular disease; BMI, body mass index; BP, 
blood pressure; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; 
FRS, Framingham Risk Score; HIV, human immunodeficiency virus; IQR, interquartile 
range; LAE, large arterial elasticity; N, number; RNA, ribonucleic acid; SAE, small arterial 
elasticity; START, Strategic Timing of AntiRetroviral Treatment. 
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Figure 1 plots HIV viral suppression and visit attendance by 
group over follow-up, indicating that 97% of immediate and 
51% of deferred participants achieved an HIV RNA level <400 
copies/mL by 36 months. Among participants in the immediate 
group, the initial ART regimen included tenofovir disoproxil 
fumarate (TDF) in 99%, efavirenz in 74%, a protease inhibitor 
([PI] predominantly darunavir or atazanavir) in 15%, and an 
integrase strand transfer inhibitor ([INSTI] all consisting of ral-
tegravir) in 7%. Among deferred group participants who started 
ART, the corresponding initial regimens included TDF in 98%, 
efavirenz in 60%, a PI in 15%, and an INSTI in 14%.
Small Arterial Elasticity
Figure 2 and Table 2 present the differences between treatment 
groups in change from baseline SAE values. The distribution 
of SAE values at each follow-up is included in a Supplemental 
Table. There was no significant difference between immediate 
and deferred ART groups in the change from baseline SAE, 
either over all of follow-up or at any of the individual fol-
low-up visits. The lack of differences persisted when examining 
changes before or after 12 months, when censoring participants 
in the deferred ART group who started ART or when adjusting 
for CVD risk factors (eg, FRS, use of lipid-lowering therapy, use 
of BP-lowering therapy, or smoking) and other demograph-
ics (age, race, and gender) (data not shown). Neither treat-
ment group demonstrated within participant changes in SAE 
over time, including analyses that focused on changes among 
deferred group participants after they started ART. Subgroup 
analyses, examining the treatment effect on changes from 
baseline in SAE, were examined, and there was no significant 
treatment by subgroup interaction (see Supplemental Figure B).
Large Arterial Elasticity
Figure 2 and Table 2 also present the data for change from base-
line in LAE over time. There was no difference between imme-
diate and deferred ART groups in the change from baseline in 
LAE values. The lack of differences persisted in secondary and 
subgroup analyses (data not shown; analyses conducted anal-
ogous to those presented for SAE). Neither treatment group 
demonstrated within participant changes in LAE over time.
Antiretroviral Regimen Effects
Among the immediate ART group, there were no significant 
differences for change in SAE or LAE by initial ART regimen 
(ie, efavirenz containing versus not, PI containing versus not, or 
raltegravir containing versus not) (data not shown).
DISCUSSION
The arterial elasticity substudy of the START trial is the first 
randomized comparison of ART initiation on vascular func-
tion, when compared with deferral of ART (ie, untreated HIV 
infection). We did not observe a significant influence of ART 
initiation on SAE or LAE. These findings challenge prior 
reports, based on cross-sectional and uncontrolled data, sug-
gesting that ART treatment may improve (or impair) vascular 
function [26–34], as well as clinical outcome data from the 
Strategic Management of AntiRetroviral Therapy trial show-
ing that continuous ART treatment was associated with lower 
CVD event rates when compared with episodic ART [35, 36]. 
Figure 1. Antiretroviral therapy (ART) use and viral suppression by treatment group over follow-up. Plots present the percentage of substudy participants in each treatment 
group that are on ART (A) and have a human immunodeficiency virus (HIV) ribonucleic acid level <400 copies/mL (B) at each visit over follow-up. The numbers of participants 
from each treatment group that attended each study visit are also listed below the x-axis. 
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Strategic Timing of AntiRetroviral Therapy is unique with 
respect to studying HIV-related CVD risk, both in terms of 
the target population (with relative immune preservation and 
at very low CVD risk overall) and the prospective controlled 
study design (ie, experimental intervention of ART initiation). 
Therefore, findings from this study both address limitations 
from prior studies and raise important questions about CVD 
risk among contemporary patients who initiate ART very early 
during HIV disease.
Several potential explanations exist for why our findings 
do not show changes in arterial elasticity with ART initiation. 
Antiretroviral therapy initiation may influence CVD risk, pos-
itively or negatively, through biology not directly assessed. 
Arterial elasticity does not directly assess nitric oxide-mediated 
endothelial dysfunction, which has been shown to improve 
after ART initiation [29, 37]. Arterial elasticity estimation 
through BP waveform analysis reflects a more mixed pathology 
including both structural and functional changes throughout 
the vasculature. Furthermore, arterial elasticity measurements 
do not directly assess atherosclerotic disease per se. Some longi-
tudinal HIV studies of imaging techniques that do assess ather-
osclerotic lesions (eg, ultrasound estimates of CIMT or carotid 
plaque prevalence, or computed tomography assessments of 
CAC) have demonstrated changes in disease progression that 
are influenced by ART use [38–41]. However, it is important to 
note that none of these data on ART-related changes in CVD 
assessments included a randomized comparison with untreated 
HIV infection.
Additional factors that may have influenced our findings 
include that participants were at low risk for CVD risk, had a 
median duration of HIV diagnosis of only 1.3 years, and were 
observed for a relatively modest duration. All of these factors 
Figure 2. Small and large arterial elasticity over time by treatment group in Strategic Timing of Antiretroviral Treatment (START). Plots present mean and change in small 
arterial elasticity ([SAE] A and C, respectively) and large arterial elasticity ([LAE] B and D, respectively) over time for both immediate and deferred groups in START. Confidence 
bounds represent 95% confidence intervals.
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may have influenced the degree to which HIV- or ART-related 
vascular damage occurred. Our ability to study the effects of 
specific antiretrovirals was also limited. Specifically, the ART 
regimen used by the immediate group included TDF in 99% 
and efavirenz in 74%, and neither drug has been associated 
with excess risk for CVD when compared with other antiretro-
virals [42, 43]. In addition, this study did not include measures 
of plasma cytokines, monocyte activation, and/or T-cell acti-
vation—all shown to be potentially important for HIV-related 
CVD pathogenesis [9, 10, 44]. Further characterization of the 
effects of ART initiation on systemic inflammation during very 
early HIV disease will be an important focus of future research 
involving START. Finally, it is worth emphasizing that both 
HIV infection and ART may exert offsetting influences on vas-
cular function [45, 46], such that the finding of no detectable 
treatment effect may be the net result of ART toxicity concur-
rent with declines in HIV-specific effects.
Our study also has risk for type-2 statistical error given our 
sample size; ie, there may be a small magnitude difference 
between immediate and deferred ART that we were unable to 
detect. However, we were able to rule out what would likely be 
a clinically meaningful difference in SAE—which is associated 
with a broad spectrum of CVD events in the MESA cohort 
[16]. If the estimate for an SAE treatment effect in our study 
was found to be significant in a larger sample (ie, an effect of 
ART initiation resulting in an improvement of SAE by 0.25 mL/
mmHg × 100), data from MESA suggest this would correspond 
to an approximate 2%–3% absolute difference in CVD event 
risk (or a 5%–8% difference at our upper confidence limit of 
0.63 SAE units).
Despite these limitations, our findings provide compelling 
randomized data suggesting that ART initiation may not affect 
CVD risk to a clinically meaningful degree among HIV-postive 
patients with preserved immunity. Indeed, the primary findings 
from START report 12 and 14 CVD events in the immediate 
and deferred ART groups, respectively, corresponding to a very 
low overall CVD event rate of 0.19/100 person-years (among 
n  =  4685 participants over a mean 3.0  years of follow-up) 
[20]. The relative immune preservation and short duration of 
HIV infection in START are particularly important consider-
ations. Much of the data demonstrating greater CVD risk at 
lower CD4 counts and at higher HIV viral loads, factors that 
improve with ART, involve studies of participants with a much 
greater degree of HIV disease progression [1, 47]. Analyses of 
CVD risk based on the level of immune depression (ie, cur-
rent and nadir CD4 count) were conducted in the D:A:D (Data 
collection on Adverse events of anti-HIV Drugs) cohort and 
demonstrated very weak associations overall that were only 
present at lower CD4+ counts [8]. Cumulatively, these obser-
vations and our results support a hypothesis that excess CVD 
risk attributable to HIV infection may simply not be apparent 
in early disease, given that the effects of HIV infection on CVD 
pathogenesis occur over the long term, whether from immune 
depletion, inflammation, and/or other disease-specific factors. 
Thus, strategies such as ART to mitigate HIV-related CVD risk 
may only have a modest benefit that will take many years to 
manifest.
CONCLUSIONS
In conclusion, we have shown that immediate ART initiation 
did not significantly improve SAE or LAE, when compared 
with randomization to ART deferral (ie, largely untreated HIV 
infection), among a diverse global population of HIV-positive 
persons with recent HIV infection and high CD4+ counts. 
These data suggest that early ART treatment does not influence 
vascular function to a clinically meaningful extent among HIV-
positive persons with preserved immunity.
Supplementary Data
Supplementary material is available at Open Forum Infectious Diseases 
online.
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